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a b s t r a c t
Both Glis, the downstream effectors of hedgehog signaling, and Zic transcription factors are required for
Myf5 expression in the epaxial somite. Here we demonstrate a novel synergistic interaction between
members of both families and Pax3, a paired-domain transcription factor that is essential for both
myogenesis and neural crest development. We show that Pax3 synergizes with both Gli2 and Zic1 in
transactivating the Myf5 epaxial somite (ES) enhancer in concert with theMyf5 promoter. This synergy is
dependent on conserved functional domains of the proteins, as well as on a novel homeodomain motif in
the Myf5 promoter and the essential Gli motif in the ES enhancer. Importantly, overexpression of Zic1
and Pax3 in the 10T1/2 mesodermal cell model results in enrichment of these factors at the endogenous
Myf5 locus and induction of Myf5 expression. In our previous work, we showed that by enhancing
nuclear translocation of Gli factors, Zics provide spatiotemporal patterning for Gli family members in the
epaxial induction of Myf5 expression. Our current study indicates a complementary mechanism in which
association with DNA-bound Pax3 strengthens the ability of both Zic1 and Gli2 to transactivate Myf5 in
the epaxial somite.
Published by Elsevier Inc.
Introduction
Development of skeletal muscle is controlled by the myogenic
regulatory factors (MRFs): Myf5, MyoD, Myogenin, and MRF4.
These transcription factors are essential for the determination
and differentiation of skeletal muscle during embryogenesis
(Francetic and Li, 2011; Pownall et al., 2002), and display the
unique ability to convert non-muscle cell types to skeletal muscle
(Weintraub et al., 1991). Myf5 is the ﬁrst MRF to be expressed, at
E8 in the mouse (Ott et al., 1991). Transcripts are ﬁrst detectable in
the dermomyotome of the earliest somites, then in the newly
formed myotome, followed by expression in the ventral dermo-
myotome and branchial arches (Ott et al., 1991). Following migra-
tion of muscle precursor cells from the somites to the limb buds,
Myf5 is also transiently activated in the developing limbs (Ott
et al., 1991; Tajbakhsh and Buckingham, 1994). In the adult, Myf5
expression is downregulated and only maintained in muscle
satellite cells and spindles (Zammit et al., 2004). Targeted disruption
of Myf5, MyoD, and MRF4 in the mouse results in a complete
absence of myoblasts, underscoring the importance of these factors
for myogenic commitment (Braun et al., 1992; Kassar-Duchossoy
et al., 2004; Rudnicki et al., 1992).
Myf5 and Mrf4 are linked, and the shared locus is subject to
complex transcriptional regulation (Francetic and Li, 2011). Manip-
ulation of the locus in transgenic reporter mice has uncovered a
number of discrete enhancers that direct expression of each gene
in speciﬁc progenitor cell populations in the embryo (Carvajal
et al., 2008). One of the best characterized enhancers in the locus
is the Myf5 epaxial somite (ES) enhancer. This region lies 6.6 kb
upstream of the Myf5 transcription start site and controls the
expression of Myf5 in the epaxial muscle progenitors of the dorsal
somite (Summerbell et al., 2000; Teboul et al., 2002). Interestingly,
while the Myf5 ES enhancer activates its own promoter, it cannot
engage productively with the closerMrf4 promoter or with several
cryptic promoters in the locus (Carvajal et al., 2008; Teboul et al.,
2003), suggesting that expression of Myf5 in the epaxial somite
requires speciﬁc interactions with its homologous promoter.
Several signaling pathways and their downstream effectors
have been implicated in activity of the Myf5 ES enhancer. Correct
expression of Myf5 in the epaxial somite requires Sonic hedgehog
(Shh) signaling via a conserved Gli motif, Wnt signaling through
multiple TCF/LEF motifs, and Dmrt2 motifs in the ES enhancer
(Borello et al., 2006; Gustafsson et al., 2002; Sato et al., 2010;
Teboul et al., 2003). Much less is known regarding control of the
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Myf5 promoter, but FoxD3 binding to a conserved motif in the
Myf5 promoter of zebraﬁsh is required for maintenance of Myf5
expression in the somites (Lee et al., 2006).
Glis and Zics are closely related zinc-ﬁnger transcription
factors, shown to have antagonistic effects in neural patterning
(Brewster et al., 1998), and cooperative effects in skeletal pattern-
ing and myogenesis (Aruga et al., 1999; Pan et al., 2011). Mutations
in both families result in a range of developmental abnormalities
(Houtmeyers et al., 2013; Hui and Angers, 2011), and members of
both families are important for Myf5 expression in the epaxial
somite (Borycki et al., 2000; McDermott et al., 2005; Pan et al.,
2011). Expression of Pax3, a paired-domain transcription factor
that is essential for both myogenesis and neural crest develop-
ment, also overlaps with that of Myf5 in myogenic progenitors in
the dermomyotome and limb buds. Pax3 has been shown to
activate several Myf5 enhancers, both directly (Bajard et al.,
2006; Daubas and Buckingham, 2013) and indirectly (Sato et al.,
2010), and mutations in Pax3 lead to Waardenburg syndrome
types I and III, diseases characterized by defects in muscle and
neural crest derivatives (Hoth et al., 1993).
Given the overlapping roles of Gli, Zic, and Pax transcription
factors in somite myogenesis, we asked whether these factors are
capable of synergizing in activating the Myf5 ES enhancer and
homologous promoter. Here we demonstrate novel synergistic
interactions between Gli2 and Pax3, and Zic1 and Pax3. This
synergy is dependent on conserved functional domains of the
proteins, as well as on a novel homeodomain motif in the Myf5
promoter and the essential Gli motif in the ES enhancer. Impor-
tantly, overexpression of Zic1 and Pax3 in the 10T1/2 mesodermal
cell model results in the enrichment of these factors at the
endogenous Myf5 locus and induction of Myf5 expression. Unlike
Gli2 and Pax3, Zic1 is expressed exclusively in epaxial muscle
progenitors within the dermomyotome. In our previous work, we
showed that Zics provide spatiotemporal patterning for Gli family
members in the induction of Myf5 expression (Pan et al., 2011).
Here we show that in addition to enhancing the nuclear transloca-
tion of Gli factors (Koyabu et al., 2001; Pan et al., 2011), Zic1 also
associates with Pax3 on the Myf5 promoter to drive Myf5 expres-
sion. Likewise, the ability of Gli2 to transactivate Myf5 is strength-
ened by a synergistic association with Pax3. Collectively, our data
indicate novel interactions that link several well-established
myogenic pathways.
Materials and methods
Plasmids and antibodies
Mammalian expression plasmids Gli1 and Gli2 in pcDNA3.1-His,
and Gli2 lacking the C-terminal domain (Gli2[ΔC2] and Gli2[ΔC4])
have been described previously (Sasaki et al., 1999). Zic1 and Zic2 in
pCS2FLAG have also been described (Pan et al., 2011). Pax3–HA in
pcDNA3 and Pax7-FLAG in pBRIT were purchased from Addgene
(♯27319 and ♯17521, respectively). Zic1 lacking the ZOC domain (Zic1
[ΔZOC]) or zinc ﬁngers (Zic1[ΔZF]), and Pax3 lacking the home-
odomain (Pax3[ΔHD]) or transactivation domain (Pax3[ΔTD]) were
made using standard site-directed mutagenesis on the plasmids
described above. The Myf5 ES enhancer, EpExt in (Borello et al.,
2006), and Myf5 promoter (Teboul et al., 2003) were ampliﬁed from
mouse genomic DNA and cloned into the ﬁreﬂy luciferase reporter
vector pGL3-Basic (Promega) to generate E-P-luc. Mutations in the ES
enhancer Gli motif (Gli-mt) (Gustafsson et al., 2002) and Myf5
promoter homeodomain motif (HD-mt) were made using standard
site-directed mutagenesis of E-P-luc. (Gli)8-TK-luc, containing eight
wild-type Gli binding sites from the Myf5 ES enhancer, has been
described (Gustafsson et al., 2002). Antibodies used in this study were:
anti-HA monoclonal antibody (sc-7392, Santa Cruz Biotechnology,
Inc.), anti-FLAG M2 monoclonal antibody (♯F3165, SIGMA), anti-Gli2
polyclonal antibody (ab7195, abcam), anti-V5 monoclonal antibody
(♯R960-25, Invitrogen), and normal mouse IgG (sc-2025, Santa Cruz
Biotechnology, Inc.).
Cell culture
NIH 3T3 mouse embryonic ﬁbroblasts and C3H/10T1/2 mouse
embryonic mesenchymal stem cells were grown in Dulbecco's
modiﬁed Eagle's medium (DMEM) (Mediatech, Inc.)þ10% fetal
bovine serum (FBS) (Denville) and antibiotics (100 U/ml penicillin
and 0.1 mg/ml streptomycin). 10T1/2 cells were also supplemented
with 10 mM HEPES.
Transient transfections and reporter assays
Cells were transfected using Lipofectamine 2000 (Invitrogen)
according to the manufacturer's protocol, and harvested at 48 h
post-transfection. For co-immunoprecipitation assays, gel-shift
assays, RT-PCR, and ChIP assays, cells were transfected with
expression constructs in 10 cm plates. For reporter assays, cells
were reverse transfected with expression and reporter constructs
in 96-well plates according to the manufacturer's protocol. To aid
cell lysis, plates were frozen at 701 for 1 h, followed by 10 min at
251, 15 min at 371, and 10 min at 251. Fireﬂy and renilla luciferase
activities were measured using the Dual-Glo Luciferase Assay
System (Promega) according to the manufacturer's protocol.
Co-immunoprecipitation and western analysis
10T1/2 cells transfected with Pax3–HA and FLAG–Zic1 expres-
sion plasmids were harvested 48 h after transfection in PBSþpro-
tease inhibitors (♯P8340, SIGMA). Cells were pelleted, washed with
PBSþprotease inhibitors, then lysed in lysis buffer (50 mM Tris,
150 mM NaCl, 1% NP-40, 1 mM Na orthovanadate, 1 mM DTT, and
protease inhibitors) for 30 min on ice. Lysates were mixed with
equal parts adjustment buffer (50 mM Tris, 150 mM NaCl), then
cell debris was pelleted and lysates transfered to new tubes.
Lysates were incubated with or without antibodies for 2 h at 4 1C
with rotation, then incubated with Protein A Sepharose beads
(♯17-5280-01, Amersham) for 2 h at 4 1C with rotation. Immuno-
precipitates were washed 3 with wash buffer (1:1 lysis buf-
ferþadjustment buffer), then resuspended in 2 SDS loading dye
and boiled for 5 min before storing at 20 1C. Proteins were
separated by SDS–polyacrylamide gel electrophoresis, transfered
to PVDF membranes, blocked 1 h at RT with 5% milk diluted in PBS,
and incubated at 4 1C overnight with anti-HA antibody diluted 1/
100 in 5% milk-PBS. Membranes were washed in PBS and incu-
bated with a horseradish peroxidase-conjugated anti-mouse anti-
body (GE Healthcare). SuperSignal West Pico Chemiluminescent
Substrate (Pierce) was used for detection.
Preparation of nuclear extracts
Crude nuclear extracts from 10T1/2 cells overexpressing Pax3–HA
were prepared as previously described (Dignam et al., 1983). Total
protein in the extracts was quantitated by the Bradford method
(Bradford, 1976).
Gel mobility shift assays
Gel-shift assays were carried out as previously described (Himeda
et al., 2008) using nuclear extracts prepared as above. Incubations with
antibodies or unlabeled oligonucleotide competitors were carried out
at room temperature for 20 min prior to the addition of probe.
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Forward sequences of oligonucleotides used as probe/competitors
are: consensus Pax3 motif from the 58/56 kb distal Myf5 enhan-
cer: 5′-GCATGACTAATTGCATGGTAACTGGAGAAA-3′ (Buchberger et al.,
2007); wt Pax3 HD motif from theMyf5 promoter: 5′-CTGGGCGTTAT-
TAGCATATCCCACC-3′; mt Pax3 HD motif from the Myf5 promoter: 5′-
CTGGGCGTTATGAGGATCTACCACC-3′. Mutated bases are underlined.
RT-PCR
RNA was extracted using the Qiagen RNeasy kit, according to
the manufacturer's instructions. RNA was DNase-treated and
reverse-transcribed as previously described (Himeda et al.,
2008). PCR was performed using 20–50 ng cDNA and Pfu DNA
polymerase with the following cycling conditions: 95 1C for 5 min,
followed by 38 cycles of 95 1C for 1 min, 51 1C for 1 min, 72 1C for
45 s, and a ﬁnal extension at 72 1C for 10 min. Primer sequences
for amplifying Myf5 and GAPDH are as described (Pan et al., 2011).
Chromatin immunoprecipitation (ChIP) assays
ChIP assays were performed with 10T1/2 cells overexpressing
FLAG–Zic1 and Pax3–HA using the Fast ChIP method (Nelson et al.,
2006) with some modiﬁcations. Cells were ﬁxed in 1% formalde-
hyde in DMEM for 10 min and dounced 10 prior to sonication.
Cells were sonicated for 8 rounds of 15-s pulses at 90% power
output on a Branson Soniﬁer 450 (VWR Scientiﬁc) to shear the
DNA to a ladder of 200–800 bp, and efﬁciency of shearing was
veriﬁed by agarose gel electrophoresis. Chromatin was immuno-
precipitated using 2 μg of speciﬁc antibodies or normal rabbit IgG.
Quantitative PCR was performed using forward and reverse
primers (300 nM) and the QuantitTect SYBR Green PCR Kit (Qia-
gen). Reaction conditions were 40 cycles of: 94 1C for 15 s, 55 1C
for 30 s, and 72 1C for 30 s. Sequences of primers are as follows:
Myf5 promoter: F: 5′-GTCAAAGGGACCAGTAAAC-3′; R: 5′-GGGG-
CTCTTTATATATTCCTG-3′; ES enhancer: F: 5′-CAAAGCCCCAGAGA-
GAGCCGGA-3′; R: 5′-CCTGGCGTGCTTTGCTCTGC-3′. PCR products
were analyzed on a 1.5% agarose gel to verify correct size of
product and speciﬁcity of primer annealing.
Results and discussion
Pax3 synergizes with Gli2 and Zic1 in transactivating the Myf5 ES
enhancer and promoter
It has been demonstrated that promoter context is critical in
determining the behavior of enhancers, and the Myf5 ES enhancer
is no exception (Gustafsson et al., 2002; Teboul et al., 2003).
To rule out potentially spurious results following the use of a non-
homologous promoter, we cloned the mouse ES enhancer and
Myf5 promoter (Teboul et al., 2003) upstream of the ﬁreﬂy
luciferase reporter for use in these studies. To test whether Gli
and Zic transcription factors cooperate with members of the Pax
family in activating the Myf5 ES enhancer, we co-transfected
expression constructs for these factors with the reporter construct
into 3T3 cells, and assayed luciferase activity (Fig. 1). 3T3 ﬁbro-
blasts represent a convenient system in which to test these
potential interactions, since these cells express low levels of Gli2
and no Pax3 or Zic factors. While overexpression of Zic1 or Pax3
alone increased activity of the reporter construct, the combination
of factors displayed a modest, but statistically signiﬁcant synergy
(Fig. 1A). Likewise, Gli2 and Pax3 synergized in activating the ES
enhancer–promoter (Fig. 1B). Interestingly, other family members
(Gli1, Zic2, and Pax7) showed no synergistic effects (Fig. 1C and D),
suggesting that factor-speciﬁc contacts are required for recruit-
ment/stabilization of coactivators.
To determine whether Gli2 and Zic1 can physically associate
with Pax3 in the absence of DNA, we made cytoplasmic extracts
from 10T1/2 cells transfected with FLAG–Zic1 and Pax3–HA. 10T1/2
cells were used because they produced high levels of the over-
expressed proteins for co-immunoprecipitaton assays. Co-immu-
noprecipitations were performed using antibodies to FLAG or
endogenous Gli2, and immunoprecipitated proteins were probed
with HA antibodies. Pax3–HA, which runs at 60 kD, was not
detected in mock-transfected lysates, only in transfected cells
(Fig. 1E). Pax3 was precipitated with antibodies to FLAG or Gli2;
by contrast, only a very faint band was detected using antibodies to
an unrelated V5 epitope (Fig. 1E). These results indicate a speciﬁc
physical interaction between Zic1–Pax3 and Gli2–Pax3.
A novel homeodomain motif in the Myf5 promoter is required for
Pax3 synergy with Gli2 and Zic1
The Pax family is structurally deﬁned by the presence of a DNA-
binding motif called a paired domain (PD). A subset of family
members, including Pax3, contain an additional DNA-binding
domain known as a paired-type homeodomain (HD) (Mansouri
et al., 1996; Noll, 1993). The PD and HD are functionally inter-
dependent and capable of modifying Pax binding to DNA (Corry
et al., 2010). Although the Myf5 ES enhancer and promoter do not
contain a consensus PD motif, multi-species sequence alignments
revealed a highly conserved single HD motif (TAAT) at –79 relative
to the transcription start site in mouse. To determine whether
Pax3 can bind this sequence, we performed gel-shift assays using
nuclear extracts from 10T1/2 cells transfected with Pax3–HA.
Pax3–HA bound to the labeled probe containing a consensus
Pax3 motif from the 58/56 kb distal Myf5 enhancer
(Buchberger et al., 2007), and this complex was supershifted with
antibodies to HA (Fig. 2A, lanes 1–2). An excess of cold competitor
oligonucleotides containing the consensus Pax3 motif competed
away this complex (Fig. 2A, lane 3). Importantly, the wild-type, but
not the mutant Myf5 promoter HD motif also competed for Pax3
binding (Fig. 2A, lanes 3–5), although not as well as the consensus
Pax3 sequence, which contains both a paired motif and a HD motif.
This indicates that Pax3 can recognize the HD motif from the Myf5
promoter, although binding is not as strong in the absence of a
paired motif.
To determine whether the HD motif is required for Pax3
synergy with Zic1 and Gli2, we performed cotransfection experi-
ments with the Myf5 reporter construct containing a mutated HD
motif, as described above. Surprisingly, Zic1 appears to be a
stronger activator of the ES enhancer–promoter construct when
the HD motif is mutated, and Pax3 is still able to activate this
construct, indicating an indirect effect of Pax3 on the ES enhancer
or Myf5 promoter (Fig. 2B). Importantly, despite the higher
individual activity of these factors, Zic1–Pax3 synergy is comple-
tely abrogated in the absence of a functional HD motif (Fig. 2B).
Likewise, Gli2–Pax3 synergy is lost on the HD-mutated construct
(Fig. 2B). These results indicate that the novel HD motif in theMyf5
promoter is required for Pax3 to synergize with both Zic1 and Gli2,
in spite of the fact that these factors can interact in the absence of
DNA. It is possible that association between Zic1/Gli2 and Pax3
helps to stabilize Pax3 binding to the HD motif in the absence of a
paired motif in the Myf5 promoter.
To conﬁrm that Pax3 does not cooperate with Gli2 in the
absence of a Pax binding site, we tested Pax3–Gli2 interactions on
a reporter construct containing 8 Gli binding sites upstream of
the Thymidine kinase (TK) promoter. As expected, Gli2 strongly
activates this construct, whereas Pax3 does not (Fig. 2C). The
combination of Gli2 and Pax3 is less potent than Gli2 alone,
demonstrating that Pax3 does not behave as a cofactor for Gli2
(Fig. 2C).
C.L. Himeda et al. / Developmental Biology 383 (2013) 7–14 9
The essential Gli motif in the Myf5 ES enhancer is required
for Pax3–Gli2 synergy
The conserved variant Gli motif in the ES enhancer is required
for maintenance of Myf5 expression in the epaxial somite via Shh
signaling (Gustafsson et al., 2002; Teboul et al., 2003), and Glis
have been demonstrated to bind this essential site (Gustafsson
et al., 2002). To verify that this sequence is required for Gli2–Pax3
synergy, we performed cotransfection experiments with a Myf5
reporter construct containing a mutation in the ES enhancer Gli
motif. As expected, synergy between Gli2 and Pax3 is abolished in
the absence of a functional Gli binding site (Fig. 2D), indicating
that Gli2 binding to the ES enhancer is required for synergy
with Pax3.
Both Zic and Gli family members bind to DNA via ﬁve C2H2-
type zinc ﬁngers, and Zics have been shown to recognize Gli
binding sites, albeit with much lower afﬁnity than Gli factors
(Mizugishi et al., 2001). To test whether Zic1 synergizes with Pax3
via binding to the Gli motif in the ES enhancer, we tested Zic1–
Pax3 interactions on the Gli-mt reporter construct. Zic1 and Pax3
are still capable of synergizing in the absence of a functional Gli
binding site, indicating that Zic1 does not require the Gli motif in
the ES enhancer to synergize with Pax3 (Fig. 2D). Furthermore,
Zic1–Pax3 synergy does not take place on a construct driven by
multiple Gli motifs (Fig. 2C), providing further evidence that Zic1
does not synergize with Pax3 via binding to Gli motifs.
In addition to recognizing Gli motifs, Zic family members have
been shown to bind a wide range of GC-rich sequences in their
target genes (Ebert et al., 2003; Mizugishi et al., 2001; Salero et al.,
2001; Yang et al., 2000). Two conserved candidate sequences in
the Myf5 promoter were able to compete for Zic1 binding in gel-
shift assays; however, mutation of either sequence had no effect
on Zic1–Pax3 synergy (data not shown). This suggests that Zic1
synergizes with Pax3 by binding to functionally redundant motifs
Fig. 1. Pax3 synergizes with Gli2 and Zic1 in transactivating the Myf5 ES enhancer and promoter. A–D. A luciferase reporter plasmid containing the Myf5 ES enhancer and
minimal promoter was transiently transfected into 3T3 cells with or without expression plasmids for Zic1, Zic2, Gli1, Gli2, Pax3, or Pax7. Cells were harvested 48 h post-
transfection and assayed for luciferase activity. Data are plotted as the mean value and standard deviation of relative luciferase activity, with activity of the reporter construct
alone set at 1. Pax3 synergizes with Zic1 (A, *¼po0.01) and Gli2 (B, *¼po0.05) in transactivating the reporter (one-tailed, one-step t-test comparing activity of factors in
combination to the sum of individual factors), whereas other combinations of factors show no synergistic effects (C–D). E. 10T1/2 cells were transfected with Pax3–HA and
FLAG–Zic1 expression plasmids, and cell extracts were immunoprecipitated with antibodies to FLAG, Gli2, or V5 (as a negative control). Immunoprecipitates were subjected
to Western analysis using HA antibodies.
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in the Myf5 promoter; however, we cannot rule out that Zic1 acts
as a transcriptional cofactor for Pax3. This is particularly difﬁcult
to test in light of the fact that Zic1 activates a wide variety
of promoters through binding to degenerate GC-rich motifs
(Merzdorf, 2007; Mizugishi et al., 2001).
Conserved regions of Pax3, Gli2, and Zic1 are required for synergy
To determine regions of the proteins required for synergy, we
tested various truncated forms of the three factors (Fig. 3A) in co-
transfection experiments with the Myf5 ES enhancer–promoter
reporter. Interestingly, Zic1 lacking the Zic–Opa conserved motif
(Zic1ΔZOC) was a more potent transactivator than full-length Zic1,
suggesting that the ZOC motif may serve a repressive function
(Fig. 3B). However, despite its higher activity, Zic1ΔZOC was
unable to synergize with Pax3, indicating that in addition to
repressing Zic1 activity, the ZOC motif is also required for
cooperative interactions with other factors (Fig. 3B). This is
consistent with previous studies indicating that this protein
domain behaves as a context-dependent activator or repressor of
transcription (Mizugishi et al., 2004). Zic factors associate with
DNA via their zinc ﬁngers; as expected, when the zinc ﬁngers of
Zic1 were removed (Zic1ΔZF), the protein had little effect on
reporter activity and was incapable of synergizing with Pax3
(Fig. 3B). Truncation of the Pax3 HD also resulted in a loss of
synergy with Zic1, further conﬁrming that DNA-binding of Pax3 is
required for synergy (Fig. 3B). Likewise, when the transactivation
domain (TD) of Pax3 was deleted, the remaining protein was
incapable of synergizing with Zic1, suggesting that the ability of
Pax3 to recruit coactivators is critical for synergy (Fig. 3B).
Interestingly, truncation of the C-terminal TD of Gli2 (ΔC2 and
ΔC4) also abrogated synergy with Pax3, but deletion of the Pax3
TD had no effect on synergy with Gli2 (Fig. 3C), suggesting that in
the context of Gli2–Pax3 interactions, it is the Gli2 TD that is
competent to recruit transcriptional coactivators. This is consistent
with studies indicating that Gli2 acts primarily as a transcriptional
activator (Ding et al., 1998; Matise et al., 1998) and is the major
transducer of Shh signaling in the mouse (McDermott et al., 2005;
Park et al., 2000). As with Pax3–Zic1, Pax3–Gli2 synergy is
dependent on the conserved HD of Pax3 (Fig. 3C).
Pax3 and Zic1 are enriched at the ES enhancer during induction of
Myf5 transcription
Zic1 has been shown to initiate expression of Myf5 in 10T1/2
cells, which can be induced to form skeletal muscle in response to
myogenic cues (Pan et al., 2011). To conﬁrm that Zic1 and Pax3
occupy the endogenous Myf5 promoter during activation of Myf5
expression, we performed chromatin immunoprecipitation (ChIP)
assays on chromatin from 10T1/2 cells overexpressing FLAG–Zic1
and Pax3-HA. Myf5 induction in the transfected cells was con-
ﬁrmed by RT-PCR (Fig. 4A). Immunoprecipitation with either
FLAG- or HA-speciﬁc antibodies yielded 2-fold enrichment
of the Myf5 promoter over that obtained with non-immune IgG
(Fig. 4B), demonstrating that these factors occupy the endogenous
Myf5 promoter during induction of Myf5 expression. Interestingly,
we also observed enrichment of FLAG–Zic1 and Pax3–HA at the ES
Fig. 2. Sequences in the Myf5 ES enhancer and promoter are required for Pax3 synergy with Gli2 and Zic1. A. Labeled probe containing a consensus Pax3 binding site from
the 58/56 kb distal Myf5 enhancer (Buchberger et al., 2007) was mixed with nuclear extracts from 10T1/2 cells overexpressing Pax3–HA, and analyzed via gel-shift
assays. Antibodies (αHA, lane 2) or competitor oligos (Pax3 consensus motif, lane 3; wt HD motif in Myf5 promoter, lane 4, and mt HD motif in Myf5 promoter, lane 5) are
indicated. The complex containing Pax3–HA bound to the probe (supershifted with αHA in lane 2) is labeled. Arrowhead indicates free probe. B. A luciferase reporter plasmid
containing the Myf5 ES enhancer and promoter with a mutation in the promoter HD motif (HD-mt) was transiently transfected into 3T3 cells with or without expression
plasmids for Zic1, Gli2, or Pax3. C. A luciferase reporter plasmid containing 8 consensus Gli motifs upstream of the thymidine kinase (TK) promoter was transiently
transfected into 3T3 cells with or without expression plasmids for Zic1, Gli2, or Pax3. D. A luciferase reporter plasmid containing the Myf5 ES enhancer and promoter with a
mutation in the ES enhancer Gli motif (Gli-mt) was transiently transfected into 3T3 cells with or without expression plasmids for Zic1, Gli2, or Pax3. For B-D, cells were
harvested and assayed, and data was analyzed as in Fig. 1. Asterisk in D indicates synergy between Zic1 and Pax3 (po0.05, one-tailed, one-step t-test comparing activity of
factors in combination to the sum of individual factors).
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enhancer, likely due to enhancer–promoter looping interactions
(Fig. 4B) (Sanyal et al., 2012).
Cooperation among several distinct pathways promotes myogenesis
in the epaxial somite
Taken together, our data suggest an intriguing new model for
cooperative interactions between Pax3 and Zic1, in which Pax3
binds its recognition motif in the Myf5 promoter via the HD and
Zic1 binds GC-rich sequences via its zinc ﬁnger domain (Fig. 5A).
Contacts between Pax3 and the ZOC motif of Zic1 (which is
normally repressive in the absence of Pax3) prevent Zic1 from
recruiting transcriptional co-repressors, while the transactivation
domain (TD) of Pax3 serves to recruit transcriptional co-activators
for gene expression (Fig. 5A).
Our work places Zic and Pax genes in the broader context of
several well-established signaling pathways that regulate myogen-
esis (Fig. 5B). As shown in our earlier work, by enhancing nuclear
translocation of Gli factors, Zics provide spatial patterning for the
Gli family, which is expressed throughout the somite, to activate
Myf5 expression in epaxial muscle progenitors (Pan et al., 2011).
In contrast to this, our current study indicates a different mechanism
of cooperativity between Zic1 and Pax3, through the establishment
of interactions that require DNA-binding and likely help to recruit
 Zic1 ( ZOC) 
 Zic1 ( ZF) 
ZOC Zn finger TD 
Zn finger
N- -C 
N- -C 
N- -C 
PD HD TD 
 Pax3 ( HD) 
 Pax3 ( TD)
 Gli2 ( C2)
 Gli2 ( C4)
TD RD 
0
2
4
6
8
10
re
l l
uc
 a
ct
iv
ity
Gli2              -       -       -      -      -       -      -       +     -       +     +      -      + 
Gli2( C2)     -      +       -     +      -       -      -       -      -       -      -       -      - 
Gli2( C4)     -      -        -     -       +      -      +      -      -       -      -       -      - 
Pax3             -      -       +     +      -      +      +      -      -       -      -       -      -   
Pax3( HD) - - -      -       -       -      -       -     +      +      -       -      - 
Pax3( TD)    -     -        -      -      -       -      -       -      -       -      -       +     + 
* 
0
5
10
15
20
25
re
l l
uc
 a
ct
iv
ity
- - - - - - - + - + + - +
- + - + - - - - - - - - -
- - - - + - + - - - - - -
- - + +     -  +  + - - - - - -
- - - - - - - - + + - - -
Zic1            
Zic1( ZOC)
Zic1( ZF)
Pax3            
Pax3( HD)
Pax3( TD) - - - - -- - - - - - + +
Fig. 3. Conserved regions of Pax3, Gli2, and Zic1 are required for synergy. A. Diagram of truncations in expression constructs encoding Zic1, Gli2, and Pax3. ZOC¼ZOC motif;
ZF¼zinc ﬁnger domain; HD¼homeodomain; TD¼transactivation domain; C2 and C4¼C terminal domains. B–C. Truncated constructs in A were tested for synergy in
transactivating the Myf5 ES enhancer and promoter as in Figs. 1–2. * in C indicates synergy (p¼0.01) between Gli2 and Pax3 (ΔTD) (one-tailed, one-step t-test comparing
activity of factors in combination to the sum of individual factors).
-RT +RT 
Myf5 
GAPDH 
1
1.2
1.4
1.6
1.8
2
2.2
2.4
2.6
FLAG-Zic1  HA-Pax3 FLAG-Zic1 HA-Pax3
-F
LA
G
 o
r H
A
/m
sI
gG
 
Myf5 prom ES enh
Fig. 4. Pax3 and Zic1 are enriched at the ES enhancer during activation of Myf5 transcription. 10T1/2 cells were transiently transfected with FLAG–Zic1 and Pax3–HA
expression plasmids. RNA was isolated for RT-PCR or cells were ﬁxed for chromatin immunoprecipitation (ChIP) analysis. A. RT-PCR was performed using primers speciﬁc for
Myf5 and GAPDH. B. ChIP assays were performed using antibodies speciﬁc for FLAG or HA or normal mouse IgG. Immunoprecipitated chromatin was analyzed by qPCR using
primers speciﬁc for the Myf5 promoter or ES enhancer. Data are represented as fold enrichment of the Myf5 promoter or ES enhancer by αFLAG or αHA relative to normal
mouse IgG.
C.L. Himeda et al. / Developmental Biology 383 (2013) 7–1412
or stabilize coactivator proteins. Interestingly, the combination of
Pax3/7 and Zic genes is sufﬁcient to induce neural crest formation in
Xenopus (Sato et al., 2005), and in the mouse, Pax3 and Zic1 are both
expressed in the dorsal neural tube (Goulding et al., 1991; Pan et al.,
2011). This indicates that in addition to driving commitment of cells
to other lineages, the presence of these factors is not sufﬁcient to
induce Myf5 expression in non-muscle tissues.
Pax3 serves to regulate Myf5 in the epaxial somite at multiple
levels – as we have shown, through direct binding of a home-
odomain motif within the promoter, as well as indirectly, via
upregulation of FoxD3 and Dmrt2 (Lee et al., 2006; Sato et al.,
2010) (Fig. 5B). Although the BMP antagonist Noggin is required
for Zic2 expression in the epaxial somite (Pan et al., 2011), the
positive signals mediating expression of Zics in this compartment
are still unknown, although Wnts secreted from the dorsal neural
tube and surface ectoderm are likely candidates. Signaling by both
canonical and non-canonical Wnts plays an important role in
myogenesis (von Maltzahn et al., 2012), and direct binding by
LEF1/β-catenin is required for full activity of the ES enhancer via
synergy with Gli (Borello et al., 2006) (Fig. 5B).
It will be interesting to determine if the novel synergistic interac-
tions described here extend to Myf5 activation/maintenance in other
muscle lineages. During embryogenesis, Pax3 is expressed in the
dorsal neural tube and PSM, followed by expression throughout the
somites which is subsequently restricted to the dermomyotome
(Goulding et al. 1994, 1991). Following this, Pax3 expression is
decreased in the epaxial somite andmaintained in hypaxial precursors
(Bober et al., 1994; Goulding et al., 1994; Williams and Ordahl, 1994).
At E12.5, Pax3 continues to be expressed in MyoD-positive regions in
the trunk and the limbs before expression is lost at later stages (Horst
et al., 2006). Pax3 directly regulates Myf5 expression in the hypaxial
somite and some hindlimb muscle precursors via binding to a
57.5 kb upstream enhancer (Bajard et al., 2006). Recently, Pax3
was also shown to be a direct regulator of the 111 kb enhancer,
which regulates expression ofMyf5 in the ventral somite and a subset
of limb muscle precursors (Daubas and Buckingham, 2013). Since Shh
was recently shown to be required forMyf5 expression in limb muscle
progenitor cells (Anderson et al., 2012; Hu et al., 2012), it will be
important to determine whether Gli2 and Pax3 synergize in driving
Myf5 expression in this muscle lineage. Although Shh is not required
forMyf5 activation in hypaxial progenitors (Borycki et al., 1999; Kruger
et al., 2001), Gli2 expression overlaps that of Myf5 in this domain
(McDermott et al., 2005). This raises the possibility that Gli2 (activated
independent of Shh signaling; possibly via FGF and PKCδ/MEK1
(Huang et al., 2003; Riobo et al., 2006)) and Pax3 synergize in
activating hypaxialMyf5 expression. Likewise, while the strong epaxial
expression of Zics closely mimics that of Pax3 at E9.5 (Pan et al., 2011),
Zic2/3 are also expressed in the limb buds and in the developing limbs
at later stages (Nagai et al., 1997). Thus, it will also be important to
determine whether Zics synergize with Pax3 in activating the hypaxial
Myf5 enhancers. Understanding the spatiotemporal dynamics of these
interactions and the mechanisms by which these factors cooperate to
drive myogenesis remains a signiﬁcant challenge for future studies.
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